Stonepine Capital Management LLC Makes New $783,678 Investment in Zentalis Pharmaceuticals, Inc. $ZNTL

Stonepine Capital Management LLC acquired a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 161,583 shares of the company’s stock, valued at approximately $783,678. Stonepine Capital Management LLC owned 0.23% of Zentalis Pharmaceuticals at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. Seven Fleet Capital Management LP raised its holdings in Zentalis Pharmaceuticals by 188.7% in the second quarter. Seven Fleet Capital Management LP now owns 317,600 shares of the company’s stock worth $1,451,000 after purchasing an additional 207,600 shares during the period. Bank of America Corp DE bought a new position in Zentalis Pharmaceuticals during the second quarter valued at approximately $5,406,000. 5AM Venture Management LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter worth approximately $19,147,378. ADAR1 Capital Management LLC bought a new stake in Zentalis Pharmaceuticals during the 2nd quarter worth approximately $3,166,000. Finally, Primecap Management Co. CA bought a new position in Zentalis Pharmaceuticals during the 2nd quarter valued at about $4,643,000.

Get Zentalis Pharmaceuticals alerts:

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, major shareholder Group Walters bought 4,335,000 shares of the company’s stock in a transaction on Friday, August 14th. The shares were bought at an average cost of $3.50 per share, for a total transaction of $15,172,500.00. Following the acquisition, the insider directly owned 17,844,973 shares in the company, valued at approximately $62,457,405.50. The trade was a 32.09% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 3.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ZNTL. Wall Street Zen cut Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Mizuho started coverage on shares of Zentalis Pharmaceuticals in a research report on Friday, July 17th. They issued an “outperform” rating and a $8.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Monday, July 6th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Finally, Rodman & Renshaw began coverage on Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They issued a “buy” rating and a $11.00 target price for the company. Four analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $6.75.

Get Our Latest Stock Analysis on Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Trading Down 2.1%

NASDAQ:ZNTL traded down $0.08 during mid-day trading on Friday, reaching $3.80. 695,395 shares of the stock were exchanged, compared to its average volume of 1,611,788. Zentalis Pharmaceuticals, Inc. has a 1-year low of $1.21 and a 1-year high of $6.95. The business has a fifty day moving average price of $4.37 and a 200 day moving average price of $3.72. The firm has a market capitalization of $272.35 million, a PE ratio of -1.95 and a beta of 1.92.

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.10). On average, sell-side analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.14 earnings per share for the current year.

Zentalis Pharmaceuticals Profile

(Free Report)

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.

Featured Stories

• Five stocks we like better than Zentalis Pharmaceuticals
• 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
• IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
• Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
• Okta Stock Surges 29%—Is $200 the Next Stop?

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.